Transforming ovarian cancer care by targeting minimal residual disease Editorial

  


Authors: Jazaeri, A. A.; Grisham, R.; Knisely, A.; Spranger, S.; Zamarin, D.; Hillman, R. T.; Lawson, B. C.; Burns, K. H.; Lee, S.; Westin, S. N.; Moiso, E.; Williams, M. J.; Bardhan, N. M.; Pisanic, T.; Matulonis, U.; Weigelt, B.; Shih, I.; Konstantinopoulos, P. A.; Gaillard, S.; Wang, L.; Aghajanian, C.; D'Andrea, A. D.; Hammond, P.; Shah, S.; Wucherpfennig, K. W.; Lu, K. H.
Title: Transforming ovarian cancer care by targeting minimal residual disease
Abstract: Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences. Copyright © 2023 Elsevier Inc. All rights reserved.
Keywords: ovarian neoplasms; minimal residual disease; neoplasm, residual; ovary tumor; ovary carcinoma; humans; human; female; carcinoma, ovarian epithelial
Journal Title: Med
Volume: 4
Issue: 11
ISSN: 2666-6359
Publisher: Cell Press  
Date Published: 2023-11-10
Start Page: 755
End Page: 760
Language: English
DOI: 10.1016/j.medj.2023.08.004
PUBMED: 37951209
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176990623&doi=10.1016%2fj.medj.2023.08.004&partnerID=40&md5=a89fd23cebdf20bfd794e6a1400ca18d
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Dmitriy Zamarin
    201 Zamarin
  2. Rachel Nicole Grisham
    170 Grisham
  3. Carol A Aghajanian
    609 Aghajanian
  4. Britta Weigelt
    635 Weigelt
  5. Sohrab Prakash Shah
    87 Shah
  6. Marc Williams
    16 Williams
Related MSK Work